Crispr Therapeutics Ord Shs (CRSP)
$84.11
4.41 (5.53%)
CRSP Stock Quote Delayed 30 Minutes
Previous Close
$84.11
Market Cap
3.94B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.57M
Day's Range
79.13 - 85.00
52-Week Range
32.30 - 85.00
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ord Shs News
The Future Could Be Soon for Crispr Therapeutics
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
3 Reasons to Go Long Crispr Therapeutics
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
CRISPR Therapeutics Is a Worthwhile Investment in Transformative Science
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Consider Adding New Positions in U.S. Cannabis Stocks
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
Why CRSP Stock Has Added Layers of Risk
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
